Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.
Seventeen children and two adolescents, aged 6 months to 20 9/12 years, with poor risk leukemia were treated with a total of 38 sequential high-dose ARA-C-Asparaginase courses (HIDAC-ASNase). Each course was followed by profound myelosuppression. Fever occurred in 13.2% and infectious complications in 7.9% of courses. Other side effects were vomiting (81.6%), drug fever (55.3%), mucositis and diarrhoea (28.9%), mild hepatotoxicity (26.3%), exanthemas (18.4%), conjunctivitis (15.8%), local ASNase hypersensitivity (7.9%), athropathy (5.3%). One patient developed generalized seizures followed by coma and death. The possible association between ARA-C, the CNS symptoms and death could neither be demonstrated nor excluded. Except for the possible ARA-C related CNS toxicity, toxic effects were reversible. We consider this treatment a tolerable chemotherapeutic contribution in childhood.
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000633:toxicity*; D001215:Asparaginase / Q000008:administration & dosage / Q000633:toxicity*; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000633:toxicity*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male
D003561:Cytarabine; D001215:Asparaginase